Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT02621021 · Melanoma
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT03340506 · Melanoma, Non Small Cell Lung Cancer, and more
Local Institution
Los Angeles, California
Local Institution
New Haven, Connecticut
Local Institution
Tampa, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions